Laboratory Findings 2018-04-05T23:06:18+00:00

Laboratory Findings

Despite extensive laboratory testing in many RTD patients, biochemical abnormalities that can be used as reliable diagnostic tools for RTDs have yet to be found.  Laboratory findings that can be used for tracking treatment effectiveness also remain elusive.

Abnormalities noted in RTD patients prior to riboflavin therapy can be mild and transient. Transient findings may be caused by fluxes in intracellular flavin levels due to changes in diet, metabolic stress from illness or surgery, or variable fasting times prior to testing.

Laboratory findings in RTD patients are often normal, with biochemical abnormalities found in less than 50% of RTD patients.  In combination with the clinical, neurophysiologic, and neuroimaging results, the presence of one or more of these abnormalities should raise suspicion of RTD prior to confirmation via genetic testing.  Abnormalities noted have included:

Plasma/Blood:

  • Abnormal acylcarnitine profile (the most common laboratory finding in RTDs)
  • Low riboflavin, flavin mononucleotide (FMN) and/or flavin adenine dinucleotide (FAD) levels
  • Signs of mild mitochondrial dysfunction, such as a mildly increased lactic acid level and specific amino acid abnormalities, including increased levels of alanine and proline
  • Low hemoglobin and serum iron and/or ferritin levels
  • Anemia (macrocytic or normocytic)

Urine organic acids

  • Increased level of ethylmalonic acid.  The profile may resemble that of multiple acyl-CoA dehydrogenation deficiency (MADD) or suggest a defect in riboflavin metabolism.

Cerebrospinal Fluid 

  • Mildly increased protein level

Acylcarnitine Profile

One of the metabolic hallmarks of RTD is abnormal mitochondrial fatty acid metabolism.  In both RTD Type 2 and 3, between 50 and 60% of patients have abnormal blood acylcarnitine profiles with, typically, increased levels of short- and medium-chain (and, rarely, long-chain) acylcarnitines. The acylcarnitine pattern in RTD sometimes resembles that of multiple acyl-CoA dehydrogenase deficiency (MADD) or may show more restricted acylcarnitine abnormalities, such as increased levels of only C6, C8 and C10 acylcarnitine species.

Other abnormalities can include a low free carnitine level and an increased acylcarnitine:free carnitine ratio. Some patients will have severely depleted total carnitine levels, which can reduce or eliminate the characteristic acylcarnitine abnormalities of RTDs.

Acylcarnitine Profile  – Newborn Screening

There is the potential for a subset of patients with RTDs to be detected by newborn screening (NBS).  After several reports of RTD Type 3 patients with no alterations in their NBS acylcarnitine profile, there were doubts that NBS could be used for early detection of RTDs (Bosch et al., 2012).  However, two patients with RTD Type 2 with mildly increased levels of medium-chain acylcarnitine species on NBS have recently been described (Rocha et al., 2016, Fu et al., 2016).  The authors hypothesized that these infants had abnormal acylcarnitine profiles, because maternal riboflavin would not normalize the newborns’ biochemical profiles, as it might in RTD Type 3, because of the intrinsic defect in cellular riboflavin uptake.  These findings raise the possibility that some cases of RTD could be detected by NBS using existing technology.

Acylcarnitine Testing

Given it’s low cost and the significant benefits of early treatment, an acylcarnitine profile should be considered for any patient with features of an RTD, even for those with a congenital-onset auditory neuropathy.

Riboflavin Levels

Vitamin B2 exists in blood as riboflavin and its derivatives, flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), which together are often termed “flavins.”  In both of RTD 2 and 3, riboflavin, FAD and FMN levels can be within their normal physiological ranges in both plasma and whole blood. As a result, blood flavin levels cannot be used for confirmation of a diagnosis of RTD.

A number of patients with both RTD Types 2 and 3 have been reported to have markedly decreased levels of riboflavin, FMN, and/or FAD in plasma and whole blood, which normalized with continued riboflavin supplementation.

Because FAD (and potentially FMN) levels have been suggested as better indicators of flavin status than a riboflavin level and remain relatively more stable over the course of the day, it has been suggested that riboflavin, FAD and FMN levels should all be monitored in patients, not just riboflavin levels alone.

Urine Organic Acids

Some patients with RTDs have abnormal urine organic acid profiles resembling those of multiple acyl-CoA dehydrogenase deficiency (MADD or “glutaric aciduria type II”) or defects in riboflavin metabolism.  Increased levels of urine organic acids found in RTD patients have included:

  • ethylmalonic acid
  • isovaleryl glycine
  • 2-hydroxyglutarate
  • glutaric acid
  • medium-chain dicarboxylic acids (chain lengths C4-C10)

Of these, an increased ethylmalonic acid level is the most commonly reported urine organic acid abnormality.,

Anemia, low hemoglobin, low iron and/or low ferritin

Riboflavin plays important roles in mobilizing ferritin iron from tissues and facilitating iron absorption from the gastrointestinal tract.  As a result, even mild to moderate riboflavin deficiency can result in anemia with a normal (normocytic”) or small (“microcytic”) red cell size (microcytic anemia).  In addition, FAD and FMN play important roles in mitochondrial function and the metabolism of vitamins B9 (folic acid) and B12.  Both folate and B12 deficiencies and mitochondrial dysfunction can result in anemia with large blood cells (“macrocytic anemia”) or normal red cell size, when iron deficiency is also present.

Although the exact causes are yet to be determined, a small subset of patients with RTD have been found to have:

  • Low (borderline low) hemoglobin level
  • Low iron and/or ferritin level
  • Low or borderline low red blood cell count.

Anemia can be macrocytic or normocytic, and the RDW (Red blood cell distribution width) can be increased.

Seven patients with RTD Type 2 have been found to have transfusion-dependent macrocytic anemia responsive to riboflavin treatment.

Riboflavin Treatment

Most biochemical abnormalities normalize with riboflavin supplementation, and cessation of riboflavin supplementation results in a recurrence of the abnormal metabolic profile despite normal dietary riboflavin intake.